This draft is great!!!! The latex looks super sharp, figures 1 and 3 are *chef kiss*, you tikz master!!

Let's not overedit the parts that may change, but here's feedback on stuff that can be fixed now. This is your poster so unless anything is actually wrong these are just suggestions and you are free to decline to implement anything. 

### 1. Frame the clinical question in plain language

The title doesn't need to name the model class. Consider leading with the clinical question in plain language and explain the graph neural network in the methods section. I'd use:

**Can Blood Vessel Networks in Ultrafast Breast MRI Predict Breast Cancer Treatment Response?**

Near the end of the motivation, explicitly state the scientific question:

> We test whether the structure of breast blood vessel networks and the way contrast changes through them improve treatment-response prediction beyond simple summaries of the same MRI measurements.

Please use **neoadjuvant treatment (NAT)** rather than **neoadjuvant chemotherapy (NAC)**. NAT isn't one uniform treatment: it varies by breast cancer subtype and can include chemotherapy, HER2-targeted treatment, and other subtype-specific regimens. The sentence saying that “NAC is an intensive treatment” currently makes it sound like every patient receives the same intervention.

Before you introduce the graph model or show the prediction pipeline, add the **biological motivation for expecting vessel-based signal**. The current draft explains why treatment-response prediction matters, but it doesn't yet explain why tumor-associated vessels might help predict it. This should be a distinct paragraph after the clinical motivation and before the scientific question. I've added that new biology paragraph to the example below:

> Neoadjuvant treatment (NAT) varies by breast cancer subtype and may include chemotherapy and HER2-targeted therapy. Only some patients achieve a pathologic complete response (pCR). Earlier prediction could avoid ineffective treatment for women unlikely to benefit and identify nonresponders who need intensified or alternative therapy.
>
> Tumors recruit abnormal vessels that can be dense, tortuous, leaky, and disorganized. Their structure and contrast-enhancement dynamics may reflect tumor biology and affect drug delivery. We test whether these vessel-network features improve pCR prediction beyond simple summaries of the same MRI measurements.

If there is room, please add citations for the clinical claims about pCR, outcomes, and NAT, as well as the claims about tumor angiogenesis and abnormal tumor vasculature.

### 2. Describe the cohort without the internal sub-source names

Don't list `simbiosys`, `uch_nac`, and `her2_naclike`. Those are internal, somewhat arbitrary cohort labels and don't help the reader understand the science. The important information is that acquisition timing is heterogeneous.

A clearer dataset paragraph would be:

> The UChicago cohort contains 181 labeled exams from 143 patients; 179 exams are analyzed here, and 35% are pCR-positive. Acquisition timing is heterogeneous: exams contain 13–24 frames spanning 96–480 seconds. [Add the reason the other two exams were excluded.] Longitudinal exams are included, and cross-validation is grouped by patient so that exams from the same patient never appear in both training and evaluation.

The patient-grouped split is important enough to repeat in the results caption: replace “shared folds” with **“shared patient-grouped folds.”**

### 3. Explain the vessel method without unnecessary implementation jargon

The name **nnU-Net** isn't very informative to most poster readers. Cite the method, but describe what it does in plain language. For example:

> A published deep-learning segmentation model identifies vessel voxels in the DCE-MRI [citation]. Our previously developed tc4d algorithm converts the vessel mask into a one-voxel-wide centerline representation that preserves vascular connectivity. The centerlines are then converted into one of three graph representations.

You can name nnU-Net in the citation or a short parenthetical if you think it matters for reproducibility, but it doesn't need to carry the explanation. tc4d is unpublished software developed during an earlier iteration of this Summer Lab project. You should add an acknowledgements section and credit the earlier student developers there. 

"We represent the vascular network of each patient’s tumor as a graph": I think at this point it would be more correct to say "we represent the vascular network of each patient's breasts as a graph". (Are we using only tumor side or both breasts?)

### 4. Fix the graph definitions and architecture diagram

- Figure 3 labels three input boxes `run_summary.json`. I understand that this may be the literal filename, but it's implementation jargon rather than a scientific description. Replace the filename with what those files actually contribute to the model—for example, **acquisition timing and preprocessing metadata**, **node-level enhancement curves**, or whatever their contents are. The audience needs to know what information enters the pipeline, not where the code stores it.
- Change **“Sementations”** to **“Segmentations.”**
- Change **“Segement-as-node”** to **“Segment-as-node.”**
- In the junction definition, a junction is a node. Use something like \(v \in V_{\mathrm{vox}}\) with \(\deg(v)>2\), not \(e \in E_{\mathrm{vox}}\).
- Make clear that the voxel nodes are vessel-centerline voxels, not all image voxels.
- Label it **Ultrafast breast MRI movie** rather than `Raw DCE-MRI “Movie”`.

The graph-representation box is fairly dense. Consider simplifying the set notation to one plain-language line per representation because Figure 1 already carries most of the explanation; this would save a lot of space (I know this would hurt, you being a math guy, just a suggestion):

- **Voxel graph:** each centerline voxel is a node; neighboring voxels are connected.
- **Junction graph:** branch points are nodes; vessel segments connect them.
- **Segment graph:** vessel segments are nodes; segments sharing an endpoint are connected.

The pretraining path in Figure 3 should show the scientific transfer clearly: **vessel curves and elapsed times → graph encoder → forecasting decoder** during pretraining, followed by **the same pretrained graph encoder → pCR prediction head** during fine-tuning.

### 5. Remove the reproducibility section and use that space for acknowledgments

The GitHub URL is already in the footer, so you don't need a separate reproducibility section repeating it. Make the footer unambiguous:

> Code: https://github.com/dsi-clinic/vanguard

Use the space from the reproducibility section for acknowledgment. Zhen and Milica for feedback/MRI physics expertise, Fred Howard for facilitating the dev data cohort. 

If there is room you can put these full blurbs, if not can compress it:

> We thank the University of Chicago Human Imaging Research Office (HIRO; RRID:SCR_018372) for coordinating imaging. HIRO is supported in part by the Virginia and D. K. Ludwig Fund for Cancer Research and NIH/NCI grant P30 CA014599.

Compute resources for this study were provided by the Randi HPC Cluster maintained by the Center for Research Informatics (CRI) at the University of Chicago. The Center for Research Informatics is funded by the Biological Sciences Division and the Institute for Translational Medicine/CTSA (NIH UL1TR002389) at the University of Chicago. 


### 6. Reconcile the plotted AUCs with the reported difference

The plot shows the best GNN at 0.624 and the visible tabular models at approximately 0.614–0.616, but the paragraph reports a best-GNN-versus-best-tabular difference of +0.002. Those values don't appear consistent.

Please calculate the point difference directly from the same pooled out-of-fold predictions used for the plotted AUCs. A paired bootstrap changes the confidence interval, but the point estimate should agree with the difference between the corresponding pooled AUCs. If the +0.002 comparison uses a baseline that isn't visible or clearly named in the figure, add or relabel that baseline.

For now can leave that stuff because these numbers are probably going to change.

Also replace internal labels such as `tier0`, `tier1`, `7-means`, and `38-feat` with descriptions of the information supplied to each model. A reader should be able to tell which comparison isolates graph structure, kinetic features, or geometry without knowing the configuration names.

### 7. Make the graph and kinetics conclusion proportional to the experiment

The two-feature GNN at chance shows that **topology plus peak time and radius is insufficient**. It doesn't by itself prove that all useful signal is in enhancement kinetics rather than the graph. Combined with the feature-matched tabular comparison, you can say:

> Full kinetic features drive most of the observed performance, and current experiments show no measurable incremental benefit from graph message passing.

This leaves open the possibility that graph structure could become useful with better learned node representations, which is exactly what the pretraining experiment is testing.

### 8. Reframe the protocol analysis as sensitivity, not proof of confounding

A protocol-only AUC of 0.593 shows that acquisition timing or cohort source is associated with outcome in this dataset. It doesn't prove that the associated model signal is nonphysiologic. Protocol adjustment can remove genuine biological or patient differences that happen to correlate with acquisition source as well as technical variation.

I'd replace **“Protocol confound”** with **“Prediction Is Sensitive to Acquisition Timing”** and write:

> Acquisition timing is associated with outcome in this cohort: a model using acquisition information without imaging features achieves an AUC of 0.593, and protocol adjustment materially changes model performance. This raises concern about protocol dependence, but doesn't determine how much of the association is technical versus biological.

I'd remove the bracket language `[0.539, 0.613]`; it isn't immediately interpretable as written.

## Changes to make after the final runs

### 9. Evaluate pretraining with the comparison that answers the real question

Don't say that the model learns “contrast flow,” because flow isn't directly observed. Say that it predicts **future enhancement at connected vessel nodes** and may therefore learn representations of how enhancement evolves across the vascular network.

The decisive result isn't forecasting loss by itself. Compare downstream pCR prediction using:

1. The encoder initialized with the self-supervised forecasting weights.
2. The identical encoder initialized randomly.

Keep the architecture, downstream inputs, patient-grouped folds, training procedure, and evaluation identical. You can report held-out forecasting error to show that the pretraining task was learned, but the pretrained-versus-random downstream comparison is what tests whether pretraining helps pCR prediction.

If pretraining doesn't improve pCR prediction, that's still a clear result: the forecasting task learned temporal dynamics but didn't transfer useful information to this downstream endpoint under the current setup.

### 10. Include the strongest simple clinical reference

If you have time, include **tumor size alone** using the same patient-grouped folds. Tumor size is a strong pCR baseline, so the audience needs it to judge whether the vessel models contribute clinically meaningful information beyond an obvious, inexpensive predictor.

### 11. Update the conclusion only after the final comparison

A proportionate provisional conclusion is:

> Enhancement features sampled along vessel centerlines predict pCR modestly, but current GNNs don't outperform matched tabular summaries. Prediction is also sensitive to heterogeneous acquisition timing. The remaining experiment is whether forecasting-based pretraining improves the same downstream graph encoder relative to random initialization.

If pretraining improves performance, the final conclusion should state the paired improvement and uncertainty. If it doesn't, retain the negative result rather than implying that pretraining helped because its forecasting loss decreased.

## Section-title map

| Current title | Suggested descriptive title |
|---|---|
| **Graph Neural Network Modeling of Breast MRI Vascular Networks for Treatment Response Prediction** | **Can Blood Vessel Networks in Ultrafast Breast MRI Predict Breast Cancer Treatment Response?** |
| **Ultrafast MRI Dataset** | **179 UChicago Exams Capture Heterogeneous Ultrafast Dynamics** |
| **Graph Representation** | **Three Graph Representations Test Whether Topology Matters** |
| **Prediction Pipeline and GNN Architecture** | **Vessel Centerlines Become Graphs for pCR Prediction** |
| **Self-supervised Pretraining** | **Forecasting Future Enhancement May Teach the Encoder Vascular Dynamics** |
| **Results** | **Current GNNs Don't Outperform Matched Tabular Summaries** |
| **Protocol confound** | **Prediction Is Sensitive to Acquisition Timing** |
| **Conclusion** | **Kinetics Carry Signal; Incremental Graph Value Remains Unproven** |

The result-dependent titles should be updated if the final pretraining experiment changes the conclusion. The pretraining title can stay even before the result because it communicates the scientific idea being tested, not an unsupported claim that pretraining succeeded.

Odds and ends I'm noticing at the end: you use both 4D DCE-MRI and "DCE-MRI movie", pick one and be consistent. Fig 4 please get rid of the GNN/tabular baseline legend, you already label in the column on the left and the legend makes the labels on the left confusing